News for AtriCure, Inc. (ATRC)

Summary AtriCure Inc (ATRC), a leader in surgical treatments for atrial fibrillation and related conditions, announced the first use of its latest innovation, t

AtriCure stock has had a recent drop of roughly 25% even as the company delivered revenue growth in the mid-teens in FY 2024. Click to read why ATRC is a Hold.

On March 5, 2025, Karen Prange, a Director at AtriCure Inc (ATRC), sold 6,100 shares of the company. Following this transaction, the insider now owns 17,828 sha

Transaction Overview On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) executed a significant reduction in its holdings of KORU Medica

On December 31, 2024, Hood River Capital Management LLC (Trades, Portfolio) made a strategic move by increasing its stake in AtriCure Inc (ATRC). The firm added

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Revenue: $465 million for 2024, a 17% growth.Adjusted EBITDA: Increased from $19 million in 2023 to $31 million in 2024.Fourth Quarter Revenue: $124.3 million,

Earnings Call Insights: AtriCure, Inc. (NASDAQ:ATRC) Q4 2024Management ViewCEO Michael Carrel emphasized that 2024 was a year of

AtriCure, Inc. (NASDAQ:ATRC) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ETCompany ParticipantsMarissa Bych - Investor RelationsMichael...

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AtriCure Inc (ATRC), a leader in surgical treatments for atrial fibrillation and related conditions, announced its fourth quarter and full-year 2024 financial r

AtriCure (ATRC) delivered earnings and revenue surprises of 46.67% and 0.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Quarterly Revenue: $124.3 million, surpassing the estimated $121.84 million, marking a 16.6% increase year-over-year.Quarterly EPS: Reported a net loss per sha

On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) made a significant move by acquiring an additional 2,851,982 shares of Health Cataly

AtriCure (ATRC) experienced a notable stock price increase of 5.04%, reaching $36.44, with a trading volume of 258,045 shares and a turnover rate of 0.53%. The

On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) executed a notable transaction involving Axogen Inc. The firm added 260,822 shares t

AtriCure (ATRC), a key player in the medical device sector, saw its stock price rise by 5.14%, reaching $35.39 per share with a trading volume of 503,107 shares

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of Snap Inc. SNAP gained 13.5% to $12.38 following better-than-ex...

The demand for automated cell culture is mainly driven by rising investments in cell-based research, advancements in cell culture technology, and an...